Stock comparison
ImmunityBio
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IBRX
ImmunityBio
Market cap
$7.56B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IBRX | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 31F | 77B | LMAT |
| Benjamin Graham | 45D | 89A | LMAT |
| Philip Fisher | 53C | 81C | LMAT |
| Peter Lynch | 52C | 67B | LMAT |
| Joel Greenblatt | 2F | 56D | LMAT |
| Charlie Munger | 53D | 68D | LMAT |
| Terry Smith | 55C | 69D | LMAT |
Side-by-side metrics
| Metric | IBRX | LMAT |
|---|---|---|
| Market cap | $7.56B | $2.23B |
| P/E (TTM) | - | 37.1x |
| EV/EBIT | - | 36.6x |
| ROIC (TTM) | -44.51% | 9.43% |
| Gross margin | 93.79% | 72.39% |
| Net margin | -6.06% | 24.35% |
| Revenue CAGR 5y | 2.32% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | - | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IBRX leads on
- EV/EBIT-vs 36.6x+192%
- Debt / Equity-vs 0.5x+136%
- P/E (TTM)-vs 37.1x+124%
- Revenue CAGR 5y2.32%vs 12.75%+94%
LMAT leads on
- ROIC (TTM)9.43%vs -44.51%+121%
- Net margin24.35%vs -6.06%+104%
- Dividend yield0.84%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.